“…If possible, obtain DNA from such regions for assessment of epigenetic alterations (compared to DNA in Point 5). - For patients engaged in Points 1, & 2, if abnormal imaging is suggestive of altered ECM structure around nutrient canals while on BP, re‐assess after being on a “drug holiday” for a period of time to determine whether the abnormalities detected while on BP are reversed.
- Based on the above research approaches, obtain blood DNA samples from the patients engaged in the above studies to assess for the presence of known genetic risk factors [discussed in Refs. [3, 44–48]], as well as others, particularly those associated with endothelial cells.
- While the availability of a relevant preclinical model would definitely offer the potential to accelerate progress, the unique structural features of the femur (bowed femur), [ 24–26 ] the possible unique genetic and/or differentiated features of the endothelial cells of the nutrient canals [reviewed in Ref. [3]], possible racial features of risk, [ 22,23 ] and regulatory aspects associated with being bipedal may diminish the potential to develop a relevant preclinical model, particularly a larger animal model that may have a higher level of potential translation to humans.
…”